Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Extension of ANAVEX2-73 in Parkinson's Disease Dementia
NCT04575259Phase 2Completed
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Oct 2019
- Primary completion
- May 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of blarcamesine in Parkinson's disease dementia (PDD), sponsored by Anavex Life Sciences Corp.. Started Oct 2019; status: completed.
02
Drugs
blarcamesine
03
Conditions
Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT04575259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575259.